indacaterol 150 μg o.d	placebo	forced expiratory volume in 1 s (FEV1) at Week 12	943	1105	Trough FEV1 (LSM ± SEM) at Week 12 was 1.48 ± 0.018 L for indacaterol and 1.35 ± 0.019 L for placebo, a clinically relevant difference of 130 ± 24 mL (p < 0.001).
indacaterol 150 μg o.d	placebo	Standardised AUC measurements for FEV1 at Week 12	1417	1687	Standardised AUC measurements for FEV1 (between 5 min and 4 h, 5 min and 1 h, and 1 and 4 h post-dose) at Week 12 were all significantly greater with indacaterol than placebo (p < 0.001), with LSM (± SEM) differences of 170 ± 24, 180 ± 24, and 170 ± 24 mL, respectively.
indacaterol 150 μg o.d	placebo	Standardised AUC measurements for FEV1 at Week 12	1417	1604	Standardised AUC measurements for FEV1 (between 5 min and 4 h, 5 min and 1 h, and 1 and 4 h post-dose) at Week 12 were all significantly greater with indacaterol than placebo (p < 0.001),
indacaterol 150 μg o.d	placebo	FEV1 after one dose	1106	1200	Trough FEV1 after one dose was significantly higher with indacaterol than placebo (p < 0.001).
indacaterol 150 μg o.d	placebo	The overall rate of adverse events (ASs)	1886	1980	The overall rates of AEs were comparable between the groups (indacaterol 49.3%, placebo 46.8%)
